10-Q: Skinvisible Faces Going Concern Doubt Amid Low Cash, High Debt

Skinvisible, Inc. reported continued net losses and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite progress in its Invisicare drug delivery technology licensing efforts.

Summary

• Skinvisible, Inc. reported a net loss of $274,427 for the three months ended June 30, 2025, an improvement from a $303,449 net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $555,432, compared to $593,821 for the same period in 2024.
• Revenues remained flat at $5,000 for the three-month period and $10,000 for the six-month period ended June 30, 2025, consistent with the prior year.
• The company's cash balance significantly decreased to $120 as of June 30, 2025, from $10,336 at December 31, 2024.
• Total current liabilities increased to $4,525,151 as of June 30, 2025, from $3,657,266 at December 31, 2024.
• The working capital deficit worsened to $4,492,049 as of June 30, 2025, from $3,615,238 at December 31, 2024.
• Cumulative net losses since inception reached $40,501,574 as of June 30, 2025.
• The company's licensee, Quoin Pharmaceuticals, received Orphan Drug Designation in Europe and Rare Pediatric Disease Designation from the FDA for QRX003 (powered by Invisicare) for Netherton Syndrome.
• Skinvisible filed provisional patent applications in May and June 2024 for transdermal delivery of obesity drugs and glucose-controlling agents using Invisicare technology.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to material weaknesses including inadequate segregation of duties and insufficient written policies.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with critically low cash, a worsening working capital deficit, and a going concern warning. While there are positive developments in product licensing and R&D, the immediate financial viability is highly questionable, and internal control weaknesses add to the risk.

Positives

• Net loss decreased for both the three-month ($274,427 vs $303,449) and six-month ($555,432 vs $593,821) periods ended June 30, 2025, compared to the prior year.
• Basic loss per common share improved to $(0.05) for the three months and $(0.10) for the six months ended June 30, 2025, from $(0.07) and $(0.13) respectively in the prior year.
• Quoin Pharmaceuticals' QRX003, utilizing Invisicare technology, received Orphan Drug Designation in Europe, potentially granting 10 years of market exclusivity if approved.
• Quoin Pharmaceuticals' QRX003 also received Rare Pediatric Disease Designation from the FDA, which could lead to a Priority Review Voucher upon NDA approval.
• Clinical trials for QRX003 in Netherton Syndrome have shown positive initial data, a clean safety profile, and significant clinical improvements, with no adverse events reported to date.
• FDA clearance was granted to recruit teen subjects into Netherton Syndrome clinical studies, potentially expanding eligible subjects and expediting recruitment.
• New provisional patent applications were filed for transdermal delivery of obesity drugs and glucose-controlling agents, opening new market opportunities for Invisicare technology.

Negatives

• The company's cash balance is critically low at $120 as of June 30, 2025, down from $10,336 at December 31, 2024.
• Total current liabilities increased significantly to $4,525,151, leading to a worsening working capital deficit of $4,492,049.
• The company has incurred cumulative net losses of $40,501,574 since its inception, indicating a long history of unprofitability.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year.
• Disclosure controls and procedures were found to be ineffective due to material weaknesses, including inadequate segregation of duties and insufficient written policies.
• Remediation efforts for internal control weaknesses are dependent on securing additional financing, which is uncertain.

Risks

• Uncertainty of profitability due to a history of losses.
• Failure to obtain adequate financing on a timely basis and on acceptable terms to continue as a going concern.
• Legislative or regulatory changes concerning skincare research and therapies.
• Risks related to operations and uncertainties related to the business plan and strategy.
• Changes in economic conditions.
• Uncertainty with respect to intellectual property rights, protecting those rights, and claims of infringement of others' intellectual property.
• Competition in the pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas.
• Cybersecurity concerns.
• Material weaknesses in internal control over financial reporting, specifically inadequate segregation of duties and insufficient written policies and procedures for accounting and financial reporting.

Future Outlook

Management plans to generate necessary funding through licensing of core products and to seek additional debt and equity funding. The company hopes to generate more revenues from existing licenses with Quoin and Ovation in the second half of 2025 and plans to enter into commercial arrangements for its newly filed patent applications in transdermal delivery for obesity and glucose-controlling agents. Operating expenses are expected to increase as licensing revenue grows.

Management Comments

• "Managements plans for the Company are to generate the necessary funding through licensing of its core products and to seek additional debt and equity funding."
• "We hope to generate more revenues from our licenses with Quoin and Ovation for the second half of 2025."
• "We also plan to enter into commercial arrangements with pharma and biotech companies to exploit our patent applications that were recently filed, and we hope to generate revenue from these efforts in the future."
• "We expect our operating expenses will increase in the future as the Company begins to generate more licensing revenue."
• "Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months."
• "We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements."
• "We plan to seek additional financing in a private equity offering to secure funding for operations."
• "There can be no assurance that we will be successful in raising additional capital."

Industry Context

Skinvisible operates in the global skincare, dermatology, and over-the-counter markets, estimated at $80 billion and $30 billion respectively, and is expanding into broader medical markets like obesity and pain management. The company's business model of out-licensing patented delivery systems aligns with a trend of pharmaceutical companies seeking external R&D due to internal downsizing. The progress of QRX003 in Netherton Syndrome, a rare pediatric disease, highlights the potential for specialized drug delivery technologies to address underserved medical needs, a key focus for biotech and pharma. The pursuit of transdermal delivery for obesity and glucose-controlling agents positions the company in highly lucrative and evolving therapeutic areas, offering potential alternatives to traditional oral/injectable therapies.

Comparison to Industry Standards

• The company's revenue of $10,000 for six months is extremely low compared to typical pharmaceutical or biotech companies, even those in early-stage development, which often secure larger upfront payments or grants.
• The cumulative net loss of over $40 million and current cash balance of $120 are indicative of a company far from industry standards for financial stability and operational self-sufficiency.
• The significant reliance on related party debt and the ongoing need for external financing are common for early-stage biotechs but the magnitude of the deficit and the going concern warning are severe.
• The progress of QRX003, particularly the FDA's Rare Pediatric Disease Designation and EMA's Orphan Drug Designation, aligns with successful strategies in the rare disease space, where such designations can accelerate development and provide market exclusivity, similar to how companies like Sarepta Therapeutics or BioMarin Pharmaceutical have navigated orphan drug development.
• The development of transdermal delivery systems for large markets like obesity and diabetes, if successful, could offer a competitive advantage by improving patient compliance and reducing side effects, a strategy pursued by larger pharmaceutical companies like Novo Nordisk or Eli Lilly with their GLP-1 agonists, though typically through different delivery mechanisms.

Corporate Governance

Related Party Transactions

• Convertible notes payable to related parties totaling $5,372,403 as of June 30, 2025. These notes originated from the conversion of accrued salaries, vacation, and outstanding convertible notes for two officers on January 31, 2023. They are unsecured, due in five years, bear 10% interest, and are convertible into common stock at $0.10 per share with warrants at $0.15 per share.
• Loans from related party totaling $13,144 as of June 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and conversion of existing convertible notes. The going concern warning poses a substantial risk to investment value. The progress of licensed products offers long-term upside potential, but immediate financial instability is a major concern.
• **Employees:** Accrued salaries and wages are a significant operating expense, and the company's financial instability could impact job security or timely payment, although some accrued salaries were converted to notes in the past.
• **Creditors:** High current liabilities and a large working capital deficit indicate a high risk of default. Related party creditors hold a substantial portion of the company's debt.
• **Customers/Licensees (Quoin, Ovation Science):** Continued R&D progress and patent filings are positive for product pipeline. However, the company's financial instability could pose a risk to its ability to support existing licenses or develop new technologies if it cannot secure funding.
• **Regulatory Authorities:** The identified material weaknesses in internal controls could lead to increased scrutiny from regulatory bodies.

Next Steps

• Generate necessary funding through licensing of core products.
• Seek additional debt and equity funding, including a private equity offering.
• Quoin Pharmaceuticals to continue working towards obtaining necessary FDA and other regulatory approvals for marketing QRX003.
• Quoin Pharmaceuticals to continue clinical studies for QRX003, including the new study applying QRX003 to a larger body surface area.
• Enter into commercial arrangements with pharmaceutical and biotech companies to exploit new patent applications for transdermal delivery of obesity and glucose-controlling agents.
• Appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management.
• Adopt sufficient written policies and procedures for accounting and financial reporting to remediate material weaknesses in internal controls.

Key Dates

Recommendation

The company's financial position is extremely precarious, with a cash balance of only $120, a rapidly worsening working capital deficit, and a stated 'substantial doubt' about its ability to continue as a going concern. While there are positive developments in its R&D pipeline and licensing agreements, particularly with Quoin Pharmaceuticals, these long-term prospects are overshadowed by immediate and severe liquidity issues and significant accumulated losses. The identified material weaknesses in internal controls further compound the risk. Without immediate and substantial capital infusion, the company faces imminent operational challenges, making it a high-risk investment with significant downside potential.

Keywords

Invisicare, drug delivery system, Netherton Syndrome, Orphan Drug Designation, Rare Pediatric Disease Designation, transdermal delivery, obesity drugs, glucose-controlling agents, pharmaceutical licensing, biotech partnerships, SEC filing, 10-Q, going concern, intellectual property, skincare technology